Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
Abstract
In the course of the last decade the therapy of renal cell
carcinoma (RCC) stepped into a new era as targeted
therapies changed protocols and the prognosis of patients as
well. Could this successful start with sunitinib and sorafenib
be continued by more potent agents? Because objective
response rates (ORR) are still far from ideal (none of them
reach 50%), other targeted molecular approaches need to
be developed.
carcinoma (RCC) stepped into a new era as targeted
therapies changed protocols and the prognosis of patients as
well. Could this successful start with sunitinib and sorafenib
be continued by more potent agents? Because objective
response rates (ORR) are still far from ideal (none of them
reach 50%), other targeted molecular approaches need to
be developed.